LeMaitre Vascular Inc (LMAT)vsMerck & Company Inc (MRK)
LMAT
LeMaitre Vascular Inc
$107.27
-4.57%
HEALTHCARE · Cap: $2.45B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 25946% more annual revenue ($65.01B vs $249.60M). MRK leads profitability with a 28.1% profit margin vs 23.1%. LMAT appears more attractively valued with a PEG of 3.25. LMAT earns a higher WallStSmart Score of 61/100 (C+).
LMAT
Buy61
out of 100
Grade: C+
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.6%
Fair Value
$59.48
Current Price
$107.27
$47.79 premium
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 23 of every $100 in revenue as profit
Strong operational efficiency at 21.8%
15.7% revenue growth
Earnings expanding 41.4% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : LMAT
The strongest argument for LMAT centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 23.1% and operating margin at 21.8%. Revenue growth of 15.7% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : LMAT
The primary concerns for LMAT are PEG Ratio, P/E Ratio. A P/E of 42.6x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
LMAT profiles as a growth stock while MRK is a value play — different risk/reward profiles.
LMAT carries more volatility with a beta of 0.67 — expect wider price swings.
LMAT is growing revenue faster at 15.7% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
LMAT scores higher overall (61/100 vs 59/100), backed by strong 23.1% margins and 15.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LeMaitre Vascular Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?